
CALL FOR PARTICIPATING CENTRES

ETHICS APPROVED · ATADEK 2026-14/670

MegaPJI

Microbiological Profile, Antibiotic Resistance Patterns, and Clinical Outcomes of Megaprosthesis Infections



Help us map which organisms cause megaprosthesis infections, and how their resistance differs across centres and countries.

01 · ORGANISMS

Pathogens and antibiotic resistance patterns, by centre and country

02 · RISK FACTORS

Host, tumour and surgical factors linked to infection and resistant organisms

03 · OUTCOMES

DAIR, one- and two-stage revision, amputation: infection control and limb salvage

WHO TO INCLUDE

Any patient with a megaprosthesis (tumour or non-tumour indication) who developed a periprosthetic joint infection, with **≥3 months** of follow-up.

HOW TO JOIN

1. Fill in the Excel datasheet, fully anonymised: one row per patient
2. Obtain local ethics approval or waiver if required
3. Send it to **drhbulut@icloud.com**

CO-AUTHORSHIP

PATIENTS	AUTHORS
10–24	**3**
25–49	**4**
50–99	**5**
100 +	**6**

DATA SUBMISSION DEADLINE **31 December 2027**

Prof. Dr. Korhan Özkan
Acıbadem University, Istanbul, Türkiye

Prof. Dr. Santiago A. Lozano-Calderón
Massachusetts General Hospital, Harvard Medical School, Boston

Dr. Andrea Sambri
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

Dr. Halil İbrahim Bulut
Data coordinator · Acıbadem Univ. Korhan Özkan Orthopedic Oncology Study Group